{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:54:36Z","timestamp":1790873676388,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016168","name":"King Hussein Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016168","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.trsl.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:55:04Z","timestamp":1788706504000},"page":"112-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological inhibition of CBP sensitizes breast cancer to DNA-damaging agents by compromising DNA repair and cell cycle pathways"],"prefix":"10.1016","volume":"297","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-3093","authenticated-orcid":false,"given":"Wafaa S.","family":"Ramadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman M.","family":"Talaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya Mudhafar","family":"Al-Azawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al-Sherief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahenaz S.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawia","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma M.","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Semreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Hersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-8587","authenticated-orcid":false,"given":"Raafat","family":"El-Awady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2026.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00018-017-2717-4","article-title":"CREBBP and p300 lysine acetyl transferases in the DNA damage response","volume":"75","author":"Dutto","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.trsl.2026.09.002_bib0002","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10565-024-09984-0","article-title":"The important role of the histone acetyltransferases p300\/CBP in cancer and the promising anticancer effects of p300\/CBP inhibitors","volume":"41","author":"Wu","year":"2025","journal-title":"Cell Biol Toxicol"},{"issue":"20","key":"10.1016\/j.trsl.2026.09.002_bib0003","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.3390\/ijms252010982","article-title":"Acetylation of histone H3 in cancer progression and prognosis","volume":"25","author":"Miziak","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2026.09.002_bib0004","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13148-021-01060-2","article-title":"The impact of CBP expression in estrogen receptor-positive breast cancer","volume":"13","author":"Ramadan","year":"2021","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.trsl.2026.09.002_bib0005","doi-asserted-by":"crossref","first-page":"9349","DOI":"10.18632\/oncotarget.2430","article-title":"Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers","volume":"5","author":"Guo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2026.09.002_bib0006","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jmg.2004.025080","article-title":"CBP truncating mutations in ovarian cancer","volume":"42","author":"Ward","year":"2005","journal-title":"J Med Genet"},{"key":"10.1016\/j.trsl.2026.09.002_bib0007","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/sj.leu.2403971","article-title":"Detection of MOZ-CBP fusion in acute myeloid leukemia with 8;16 translocation","volume":"19","author":"Crowley","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.trsl.2026.09.002_bib0008","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/jcp.2005.029165","article-title":"Expression of HDAC1 and CBP\/p300 in human colorectal carcinomas","volume":"60","author":"Ishihama","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.trsl.2026.09.002_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13059-025-03528-3","article-title":"The histone acetyltransferase CBP participates in regulating the DNA damage response through ATM after double-strand breaks","volume":"26","author":"Ramadan","year":"2025","journal-title":"Genome Biol"},{"key":"10.1016\/j.trsl.2026.09.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100988","article-title":"22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage","volume":"8","author":"Ramadan","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.trsl.2026.09.002_bib0011","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41388-024-03148-4","article-title":"AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer","volume":"43","author":"Sardar","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.trsl.2026.09.002_bib0012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jb\/mvad034","article-title":"Acetylation of MLH1 by CBP increases cellular DNA mismatch repair activity","volume":"174","author":"Zhang","year":"2023","journal-title":"J Biochem"},{"key":"10.1016\/j.trsl.2026.09.002_bib0013","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cell.2023.11.022","article-title":"Metabolic regulation of homologous recombination repair by MRE11 lactylation","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2026.09.002_bib0014","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"18","key":"10.1016\/j.trsl.2026.09.002_bib0015","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.3390\/cancers13184614","article-title":"CBP\/p300 bromodomain inhibitor-I-CBP112 declines transcription of the Key ABC transporters and sensitizes cancer cells to chemotherapy drugs","volume":"13","author":"Strachowska","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trsl.2026.09.002_bib0016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.freeradbiomed.2025.03.034","article-title":"The clinical-grade CBP\/p300 inhibitor CCS1477 represses the global NRF2-dependent cytoprotective transcription program and re-sensitizes cancer cells to chemotherapeutic drugs","volume":"233","author":"Wang","year":"2025","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.trsl.2026.09.002_bib0017","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2014.03.015","article-title":"C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe","volume":"111","author":"Oike","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.trsl.2026.09.002_bib0018","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1038\/jid.2013.187","article-title":"Selective Inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells","volume":"133","author":"Yan","year":"2013","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.trsl.2026.09.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2022.104660","article-title":"Unveiling the mechanism of action of nature-inspired anti-cancer compounds using a multi-omics approach","volume":"265","author":"Soares","year":"2022","journal-title":"J Proteom"},{"key":"10.1016\/j.trsl.2026.09.002_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911975","article-title":"Multi-omics analysis revealed a significant alteration of critical metabolic pathways due to sorafenib-resistance in Hep3B cell lines","volume":"23","author":"Abushawish","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2026.09.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177001","article-title":"Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy","volume":"983","author":"Ramadan","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.trsl.2026.09.002_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21315\/mjms2017.24.5.11","article-title":"Sample size calculation in animal studies using resource equation approach","volume":"24","author":"Arifin","year":"2017","journal-title":"Malays J Med Sci"},{"key":"10.1016\/j.trsl.2026.09.002_bib0023","doi-asserted-by":"crossref","first-page":"23933","DOI":"10.18632\/oncotarget.8207","article-title":"Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2\/REST pathway in human breast cancer","volume":"7","author":"Xiong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2026.09.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89530-8","article-title":"C646 inhibits G2\/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer","volume":"11","author":"Ono","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2026.09.002_bib0025","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.7150\/thno.46082","article-title":"Acetylation dependent functions of Rab22a-NeoF1 fusion protein in osteosarcoma","volume":"10","author":"Liang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.trsl.2026.09.002_bib0026","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41416-022-01815-5","article-title":"Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic","volume":"127","author":"Tontsch-Grunt","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2026.09.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70395","article-title":"Improved therapeutic efficacy of doxorubicin chemotherapy with cannabidiol in 4T1 mice breast cancer model","volume":"13","author":"Tabatabaei","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.trsl.2026.09.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109139","article-title":"Magnoflorine improves sensitivity to doxorubicin (DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT\/mTOR and p38 signaling pathways","volume":"121","author":"Wei","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.trsl.2026.09.002_bib0029","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3892\/ol.2014.2050","article-title":"Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice","volume":"7","author":"Meng","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.trsl.2026.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Chang","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.trsl.2026.09.002_bib0031","series-title":"Bancroft\u2019s Theory and Practice of Histological Techniques","first-page":"173","article-title":"10 - The hematoxylins and eosin","author":"Bancroft","year":"2013"},{"key":"10.1016\/j.trsl.2026.09.002_bib0032","article-title":"Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2026.09.002_bib0033","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.trsl.2026.09.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.trsl.2026.09.002_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101056","article-title":"Chemotherapeutic drugs: cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?","volume":"14","author":"Mollaei","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.trsl.2026.09.002_bib0036","series-title":"Epigenetics in Human Disease","first-page":"85","article-title":"Chapter 4 - Alterations of histone modifications in cancer","author":"Saber-Ayad","year":"2024"},{"key":"10.1016\/j.trsl.2026.09.002_bib0037","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/onc.2010.592","article-title":"Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI\/SNF chromatin remodeling and the recruitment of non-homologous end joining factors","volume":"30","author":"Ogiwara","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.trsl.2026.09.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052810","article-title":"CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes","volume":"7","author":"Ogiwara","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2026.09.002_bib0039","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1093\/nar\/gku533","article-title":"CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis","volume":"42","author":"Cazzalini","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.trsl.2026.09.002_bib0040","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.dnarep.2012.08.001","article-title":"p300\/CBP acetyl transferases interact with and acetylate the nucleotide excision repair factor XPG","volume":"11","author":"Tillhon","year":"2012","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.trsl.2026.09.002_bib0041","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/cr500452k","article-title":"Protein lysine acetylation by p300\/CBP","volume":"115","author":"Dancy","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.trsl.2026.09.002_bib0042","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00018-016-2130-4","article-title":"The DNA damage-induced cell death response: a roadmap to kill cancer cells","volume":"73","author":"Matt","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.trsl.2026.09.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-resolved analysis reveals rapid dynamics and broad scope of the CBP\/p300 acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2026.09.002_bib0044","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trecan.2019.11.009","article-title":"Metabolic Fitness and Plasticity in Cancer Progression","volume":"6","author":"McGuirk","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trsl.2026.09.002_bib0045","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41467-021-22445-0","article-title":"Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling","volume":"12","author":"Huang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2026.09.002_bib0046","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1101\/gr.226019.117","article-title":"Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis","volume":"28","author":"Franco","year":"2018","journal-title":"Genome Res"},{"issue":"12","key":"10.1016\/j.trsl.2026.09.002_bib0047","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/cancers10120525","article-title":"CBP\/\u03b2-Catenin\/FOXM1 is a novel therapeutic target in triple negative breast cancer","volume":"10","author":"Ring","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.trsl.2026.09.002_bib0048","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3390\/cancers13112799","article-title":"Pharmacological inhibition of CBP\/p300 blocks Estrogen Receptor Alpha (ER\u03b1) function through suppressing enhancer H3K27 acetylation in luminal breast cancer","volume":"13","author":"Waddell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trsl.2026.09.002_bib0049","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13148-021-01060-2","article-title":"The impact of CBP expression in estrogen receptor-positive breast cancer","volume":"13","author":"Ramadan","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"14","key":"10.1016\/j.trsl.2026.09.002_bib0050","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3390\/molecules31142426","article-title":"Advances in mechanism of action and efficacy of CBP\/p300 inhibitors in different subtypes of breast cancer","volume":"31","author":"Yang","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.trsl.2026.09.002_bib0051","series-title":"Guide for the Care and Use of Laboratory Animals","author":"Council","year":"2011"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524426001878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:55:11Z","timestamp":1790870111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524426001878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"alternative-id":["S1931524426001878"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.09.002","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of CBP sensitizes breast cancer to DNA-damaging agents by compromising DNA repair and cell cycle pathways","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}